Similar articles

• Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.

  Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Lazar LD, et al. Circulation. 2011 Jul 12;124(2):146-53. doi: 10.1161/CIRCULATIONAHA.110.986349. Epub 2011 Jun 27. Circulation. 2011. PMID: 21709063
• Statins for cardiovascular prevention according to different strategies: a cost analysis.

  Ito MK, Nanchen D, Rodondi N, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P. Ito MK, et al. Am J Cardiovasc Drugs. 2011;11(1):33-44. doi: 10.2165/11586760-000000000-00000. Am J Cardiovasc Drugs. 2011. PMID: 21265581
• Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?

  van Hout BA, Simoons ML. van Hout BA, et al. Eur Heart J. 2001 May;22(9):751-61. doi: 10.1053/euhj.2000.2308. Eur Heart J. 2001. PMID: 11350107
• Drug insight: Statin use in the elderly.

  Raffel OC, White HD. Raffel OC, et al. Nat Clin Pract Cardiovasc Med. 2006 Jun;3(6):318-28. doi: 10.1038/ncpcardio0558. Nat Clin Pract Cardiovasc Med. 2006. PMID: 16729010 Review.
• Cost effectiveness of statins in coronary heart disease.

  Franco OH, Peeters A, Looman CW, Bonneux L. Franco OH, et al. J Epidemiol Community Health. 2005 Nov;59(11):927-33. doi: 10.1136/jech.2005.034900. J Epidemiol Community Health. 2005. PMID: 16234419 Free PMC article. Review.